GSK plc Form 6-K: Report of foreign private issuer
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-12-23: Form 6-K; Period of report 2021-12-23; Description DIRECTOR/PDMR SHAREHOLDING; Document a6678w.htm.
- 2021-12-22: Form 6-K; Period of report 2021-12-22; Description DIRECTOR/PDMR SHAREHOLDING; Document a5333w.htm.
- 2021-12-21: Form 6-K; Period of report 2021-12-21; Description VIIV HEALTHCARE ANNOUNCES FDA APPROVAL OF APRETUDE; Document a2753w.htm.
- 2021-12-20: Form 6-K; Period of report 2021-12-20; Description CONSUMER HEALTHCARE CHAIR DESIGNATE APPOINTED; Document a1222w.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2021-12-23 | 6-K | 2021-12-23 | DIRECTOR/PDMR SHAREHOLDING | a6678w.htm |
| 2021-12-22 | 6-K | 2021-12-22 | DIRECTOR/PDMR SHAREHOLDING | a5333w.htm |
| 2021-12-21 | 6-K | 2021-12-21 | VIIV HEALTHCARE ANNOUNCES FDA APPROVAL OF APRETUDE | a2753w.htm |
| 2021-12-20 | 6-K | 2021-12-20 | CONSUMER HEALTHCARE CHAIR DESIGNATE APPOINTED | a1222w.htm |
| 2021-12-17 | 6-K | 2021-12-17 | XEVUDY APPROVED IN EUROPE TO TREAT COVID-19 | a0734w.htm |
| 2021-12-15 | 6-K | 2021-12-15 | GSK/SANOFI COVID-19 VACCINE BOOSTER & PH3 UPDATE | a7156v.htm |
| 2021-12-13 | 6-K | 2021-12-13 | DIRECTOR/PDMR SHAREHOLDING | a4465v.htm |
| 2021-12-13 | 6-K | 2021-12-13 | DIRECTOR/PDMR SHAREHOLDING | a4555v.htm |
| 2021-12-07 | 6-K | 2021-12-07 | MEDICAGO/GSK COVID-19 VACCINE POSITIVE PH3 DATA | a8516u.htm |
| 2021-12-07 | 6-K | 2021-12-07 | SOTROVIMAB RETAINS ITS ACTIVITY VS OMICRON VARIANT | a8047u.htm |
| 2021-12-02 | 6-K | 2021-12-02 | SOTROVIMAB RETAINS ITS ACTIVITY VS OMICRON VARIANT | a3505u.htm |
| 2021-12-01 | 6-K | 2021-12-01 | TOTAL VOTING RIGHTS | a2337u.htm |
| 2021-11-24 | 6-K | 2021-11-24 | DIRECTOR/PDMR SHAREHOLDING | a5037t.htm |
| 2021-11-24 | 6-K | 2021-11-24 | GSK PUBLISHES PROVISIONAL 2022 DIVIDEND DATES | a5024t.htm |
| 2021-11-23 | 6-K | 2021-11-23 | DIRECTOR/PDMR SHAREHOLDING | a3168t.htm |
| 2021-11-17 | 6-K | 2021-11-17 | NUCALA APPROVED IN EUROPE FOR MORE INDICATIONS | a6094s.htm |
| 2021-11-15 | 6-K | 2021-11-15 | BLOCK LISTING INTERIM REVIEW | a4372s.htm |
| 2021-11-12 | 6-K | 2021-11-12 | PHASE III IM ADMINISTRATION DATA FOR SOTROVIMAB | a2566s.htm |
| 2021-11-12 | 6-K | 2021-11-12 | DIRECTOR/PDMR SHAREHOLDING | a2292s.htm |
| 2021-11-10 | 6-K | 2021-11-10 | DIRECTOR/PDMR SHAREHOLDING | a9635r.htm |
| 2021-11-05 | 6-K | 2021-11-05 | GSK SHARES POSITIVE PHASE III DATA FOR DAPRODUSTAT | a5599r.htm |
| 2021-11-01 | 6-K | 2021-11-01 | TOTAL VOTING RIGHTS | a9776q.htm |
| 2021-10-27 | 6-K | 2021-10-27 | 3RD QUARTER RESULTS | a4369q.htm |
| 2021-10-27 | 6-K | 2021-10-27 | DIRECTOR/PDMR SHAREHOLDING | a4677q.htm |
| 2021-10-27 | 6-K | 2021-10-27 | DIRECTORATE CHANGE | a4161q.htm |
| 2021-10-15 | 6-K | 2021-10-15 | DIRECTOR/PDMR SHAREHOLDING | a2788p.htm |
| 2021-10-14 | 6-K | 2021-10-14 | DIRECTOR/PDMR SHAREHOLDING | a1471p.htm |
| 2021-10-14 | 6-K | 2021-10-14 | DIRECTOR/PDMR SHAREHOLDING | a1467p.htm |
| 2021-10-13 | 6-K | 2021-10-13 | DIRECTOR/PDMR SHAREHOLDING | a9833o.htm |
| 2021-10-12 | 6-K | 2021-10-12 | DIRECTOR/PDMR SHAREHOLDING | a8410o.htm |
| 2021-10-12 | 6-K | 2021-10-12 | DIRECTOR/PDMR SHAREHOLDING | a8315o.htm |
| 2021-10-12 | 6-K | 2021-10-12 | DIRECTOR/PDMR SHAREHOLDING | a8313o.htm |
| 2021-10-12 | 6-K | 2021-10-12 | DIRECTOR/PDMR SHAREHOLDING | a8306o.htm |
| 2021-10-12 | 6-K | 2021-10-12 | DIRECTOR/PDMR SHAREHOLDING | a8300o.htm |
| 2021-10-01 | 6-K | 2021-10-01 | TOTAL VOTING RIGHTS | a7626n.htm |
| 2021-09-24 | 6-K | 2021-09-24 | DIRECTOR/PDMR SHAREHOLDING | a9686m.htm |
| 2021-09-22 | 6-K | 2021-09-22 | DIRECTOR/PDMR SHAREHOLDING | a6603m.htm |
| 2021-09-20 | 6-K | 2021-09-20 | DIRECTOR DECLARATION | a3496m.htm |
| 2021-09-13 | 6-K | 2021-09-13 | DIRECTOR/PDMR SHAREHOLDING | a6236l.htm |
| 2021-09-09 | 6-K | 2021-09-09 | DIRECTOR/PDMR SHAREHOLDING | a3249l.htm |
| 2021-09-07 | 6-K | 2021-09-07 | DIRECTOR/PDMR SHAREHOLDING | a0278l.htm |
| 2021-09-03 | 6-K | 2021-09-03 | DIRECTOR/PDMR SHAREHOLDING | a6849k.htm |
| 2021-09-01 | 6-K | 2021-09-01 | TOTAL VOTING RIGHTS | a4002k.htm |
| 2021-08-31 | 6-K | 2021-08-31 | SK BIO & GSK START PH3 COVID-19 VACCINE TRIAL | a1132k.htm |
| 2021-08-25 | 6-K | 2021-08-25 | DIRECTOR/PDMR SHAREHOLDING | a7831j.htm |
| 2021-08-23 | 6-K | 2021-08-23 | DIRECTOR/PDMR SHAREHOLDING | a5143j.htm |
| 2021-08-13 | 6-K/A | 2021-08-13 | DIRECTOR/PDMR SHAREHOLDING - AMENDMENT | a5968i.htm |
| 2021-08-11 | 6-K | 2021-08-11 | DIRECTOR/PDMR SHAREHOLDING | a3428i.htm |
| 2021-08-11 | 6-K | 2021-08-11 | DIRECTOR/PDMR SHAREHOLDING | a3323i.htm |
| 2021-08-05 | 6-K | 2021-08-05 | BLOCK LISTING APPLICATION | a6221h.htm |
| 2021-08-02 | 6-K | 2021-08-02 | TOTAL VOTING RIGHTS | a2878h.htm |
| 2021-07-28 | 6-K | 2021-07-28 | 2ND QUARTER RESULTS | a7663g.htm |
| 2021-07-28 | 6-K | 2021-07-28 | DIRECTOR/PDMR SHAREHOLDING | a8170g.htm |
| 2021-07-26 | 6-K | 2021-07-26 | DIRECTOR/PDMR SHAREHOLDING | a5103g.htm |
| 2021-07-23 | 6-K | 2021-07-23 | BOARD COMMITTEE CHANGES | a3383g.htm |
| 2021-07-22 | 6-K | 2021-07-22 | CEO DESIGNATE OF NEW CONSUMER HEALTHCARE COMPANY | a1823g.htm |
| 2021-07-16 | 6-K | 2021-07-16 | GSK ANNOUNCES DAPRODUSTAT PHASE 3 HEADLINE RESULTS | a5069f.htm |
| 2021-07-16 | 6-K | 2021-07-16 | DIRECTOR/PDMR SHAREHOLDING | a4856f.htm |
| 2021-07-15 | 6-K | 2021-07-15 | DIRECTOR/PDMR SHAREHOLDING | a4024f.htm |
| 2021-07-14 | 6-K | 2021-07-14 | DIRECTOR/PDMR SHAREHOLDING | a2676f.htm |
| 2021-07-14 | 6-K | 2021-07-14 | DIRECTOR/PDMR SHAREHOLDING | a2654f.htm |
| 2021-07-13 | 6-K | 2021-07-13 | DIRECTOR/PDMR SHAREHOLDING | a0589f.htm |
| 2021-07-13 | 6-K | 2021-07-13 | DIRECTOR/PDMR SHAREHOLDING | a0572f.htm |
| 2021-07-12 | 6-K | 2021-12-07 | DIRECTOR/PDMR SHAREHOLDING | a9145e.htm |
| 2021-07-12 | 6-K | 2021-07-12 | DIRECTOR/PDMR SHAREHOLDING | a9140e.htm |
| 2021-07-09 | 6-K | 2021-07-09 | DIRECTOR/PDMR SHAREHOLDING | a7512e.htm |
| 2021-07-02 | 6-K | 2021-07-02 | GSK AND ALECTOR COLLABORATION IN IMMUNO-NEUROLOGY | a0461e.htm |
| 2021-07-02 | 6-K | 2021-07-02 | ELLIOTT ADVISORS (UK) LETTER TO GSK | a0175e.htm |
| 2021-07-01 | 6-K | 2021-07-01 | TOTAL VOTING RIGHTS | a8984d.htm |
| 2021-06-25 | 6-K | 2021-06-25 | DIRECTOR/PDMR SHAREHOLDING | a2217d.htm |
| 2021-06-24 | 6-K | 2021-06-24 | DIRECTOR/PDMR SHAREHOLDING | a0131d.htm |
| 2021-06-23 | 6-K | 2021-06-23 | GSK TO DELIVER STEP-CHANGE IN GROWTH & PERFORMANCE | a8486c.htm |
| 2021-06-22 | 6-K | 2021-06-22 | VIIV/HALOZYME SIGN EXCLUSIVE LICENSING AGREEMENT | a6222c.htm |
| 2021-06-14 | 6-K | 2021-06-14 | GSK AND ITEOS ANNOUNCE COLLABORATION FOR EOS-448 | a7782b.htm |
| 2021-06-11 | 6-K | 2021-06-11 | DIRECTOR/PDMR SHAREHOLDING | a7012b.htm |
| 2021-06-09 | 6-K | 2021-06-09 | DIRECTOR/PDMR SHAREHOLDING | a3789b.htm |
| 2021-06-04 | 6-K | 2021-06-04 | TRC CAPITAL LETTER | a9338a.htm |
| 2021-06-01 | 6-K | 2021-06-01 | TOTAL VOTING RIGHTS | a4328a.htm |
| 2021-05-27 | 6-K | 2021-05-27 | DIRECTOR/PDMR SHAREHOLDING | a0276a.htm |
| 2021-05-27 | 6-K | 2021-05-27 | SANOFI AND GSK INITIATE NEW PHASE 3 CLINICAL STUDY | a0104a.htm |
| 2021-05-27 | 6-K | 2021-05-27 | GSK/VIR SOTROVIMAB FDA EMERGENCY USE AUTHORIZATION | a9654z.htm |
| 2021-05-24 | 6-K | 2021-05-24 | DIRECTOR/PDMR SHAREHOLDING | a5775z.htm |
| 2021-05-21 | 6-K | 2021-05-21 | GSK/VIR SOTROVIMAB RECEIVES POSITIVE EMA OPINION | a4767z.htm |
| 2021-05-18 | 6-K | 2021-05-18 | BLOCK LISTING INTERIM REVIEW | a0307z.htm |
| 2021-05-18 | 6-K | 2021-05-18 | MEDICAGO/GSK COVID-19 VACCINE POSITIVE PH2 RESULTS | a9627y.htm |
| 2021-05-17 | 6-K | 2021-05-17 | SANOFI/GSK COVID-19 VACCINE POSITIVE PH2 RESULTS | a8032y.htm |
| 2021-05-13 | 6-K | 2021-05-13 | DIRECTOR/PDMR SHAREHOLDING | a5958y.htm |
| 2021-05-11 | 6-K | 2021-05-11 | DIRECTOR/PDMR SHAREHOLDING | a2602y.htm |
| 2021-05-11 | 6-K | 2021-05-11 | EMTN PROSPECTUS | a2481y.htm |
| 2021-05-06 | 6-K | 2021-05-06 | BOARD AND COMMITTEE CHANGES | a8441x.htm |
| 2021-05-05 | 6-K | 2021-05-05 | RESULT OF AGM | a6939x.htm |
| 2021-05-04 | 6-K | 2021-05-04 | TOTAL VOTING RIGHTS | a5196x.htm |
| 2021-04-28 | 6-K | 2021-04-28 | DIRECTOR/PDMR SHAREHOLDING | a9774w.htm |
| 2021-04-28 | 6-K | 2021-04-28 | 1ST QUARTER RESULTS | a8880w.htm |
| 2021-04-26 | 6-K | 2021-04-26 | DIRECTOR/PDMR SHAREHOLDING | a6337w.htm |
| 2021-04-23 | 6-K | 2021-04-23 | EU APPROVES GSK'S JEMPERLI (DOSTARLIMAB-GXLY) | a4894w.htm |
| 2021-04-23 | 6-K | 2021-04-23 | FDA APPROVES GSK'S JEMPERLI (DOSTARLIMAB-GXLY) | a3745w.htm |
| 2021-04-16 | 6-K | 2021-04-16 | DIRECTOR/PDMR SHAREHOLDING | a7872v.htm |
| 2021-04-15 | 6-K | 2021-04-15 | DIRECTOR/PDMR SHAREHOLDING | a6397v.htm |
| 2021-04-15 | 6-K | 2021-04-15 | DIRECTOR/PDMR SHAREHOLDING | a5956v.htm |